TRAIL

TRAIL Informations sur la molécule

Nom anglais	Tumor necrosis factor ligand superfamily member 10	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Tumor necrosis factor ligand superfamily member 10
Alias de la cible	CD253，Apo-2 ligand，TNFSF10，TNF Superfamily Member 10，APO2L，Tumor Necrosis Factor Apoptosis-Inducing Ligand Splice Variant Delta，Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor (Ligand) Family， Member 10，TNF-Related Apoptosis Inducing Ligand TRAIL，TNF-Related Apoptosis-Inducing Ligand，Tumor Necrosis Factor Ligand 6A，CD253 Antigen，Protein TRAIL，TNLG6A，TL2，TRAIL，Apo-2L，Tumor Necrosis Factor (Ligand) Superfamily， Member 10，Chemokine Tumor Necrosis Factor Ligand Superfamily Member 10，Tumor Necrosis Factor Superfamily Member 10
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 2 Clinical

TRAIL Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
Fc Tag (1)His Tag (1)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
TRL-H5243	Human	HEK293	Human TRAIL / TNFSF10 Protein, His Tag, active trimer (MALS verified)				Ajouter au panier
TRL-H5263	Human	HEK293	Human TRAIL / TNFSF10 Protein, Fc Tag, active trimer (MALS verified)				Ajouter au panier

Quantité totale2

TRAILContexte de la molécule

TRAIL, also known as TNFSF10, APO2L, Apo-2L, CD253, TL2, TRAIL, TNLG6A and TNF superfamily member 10. The TRAIL gene as a drug target, induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

TRAILAlias de la molécule

Apo-2L,TRAIL,CD253,TNFSF10,Apo-2 ligand

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
AS-1501	AS-1501	Phase 2 Clinical	Shenzhen Zhongke Amshenn Pharmaceutical Co Ltd	Acute-On-Chronic Liver Failure; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Hepatic Insufficiency; Hepatitis; Liver Failure; Myocardial Infarction; Reperfusion Injury	Details